American Society of Hematology Annual Meeting 2022
The Mass General Cancer Center will present their latest research at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans, LA. In its 64th year, the ASH Annual Meeting & Exposition offers educational meetings and workshops for hematology professionals from around the world.
The 64th annual 2022 American Society of Hematology (ASH) Annual Meeting takes place in-person in New Orleans, LA, and virtually. The ASH Annual Meeting & Exposition offers educational meetings and workshops for hematology professionals from around the world.
The Mass General Cancer Center will have a strong presence at this year's event, with dozens of leaders scheduled to present their latest hematologic research and lead educational sessions.
Friday, December 9, 2022
Annemarie E. Fogerty, MD
1:30 pm: River City Ballroom (Mardi Gras World)
Session: Blood Buddies: Adult Clinical Classical Hematology (In-Person)
Saturday, December 10, 2022
Hanny Al-Samkari, MD
8:00 am: Camp (Hilton New Orleans Riverside)
Session: ITP/TTP—and Other Scary Causes of Thrombocytopenia
David Kuter, MD, DPhil
9:30 am: 291-292
Warm AIHA and the Best Treatment Strategies
Jacob Soumerai, MD
9:30 am: La Nouvelle Orleans Ballroom C
Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination With the BTK Inhibitor Zanubrutinib in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)
Noopur S. Raje, MD
12:00 pm: R02-R05
Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients With Relapsed or Refractory Multiple Myeloma
Mark B. Leick, MD
2:00 pm: La Nouvelle Orleans Ballroom AB
Patients With Deleterious Germline Variants in STXBP2 Develop Toxicity After CAR-T Cell Therapy With Axicabtagene Ciloleucel
Hanny Al-Samkari, MD
4:00 pm: 243-245
Chemotherapy-Induced Thrombocytopenia
Jeremy S. Abramson, MD
5:30 pm: Hall D
Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) With Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)
Philip Amrein, MD
5:30 pm: Hall D
Phase I Study of Ixazomib With Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults
Amir Fathi, MD
5:30 pm: Hall D
A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults With Acute Myeloid Leukemia
Patrick Johnson, MD
5:30 pm: Hall D
Longitudinal Patient-reported Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy
David Kuter, MD, DPhil
5:30 pm: Hall D
Phase 3, Randomized, Double-blind, Placebo-controlled, Global Study (FORWARD) of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Rachel Rosovsky, MD, MPH
5:30 pm: Hall D
Patients Reporting of Breathlessness After Experiencing Venous Thromboembolic Event
Sunday, December 11, 2022
Anna Marneth, PhD
9:30 am: 275-277
Mutant Srsf2 Diminishes Jak2V617F-Induced Erythrocytosis in Mice and Is Associated With Lower Hemoglobin in Patients With Chronic Phase JAK2-Mutant MPN
Zachariah DeFilipp, MD
12:00 pm: 208-210
Spatial Transcriptomics of Tissue-based Immune Response to Acute Graft-Versus-Host Disease of the Lower Gastrointestinal Tract
Jeremy S. Abramson, MD
4:30 pm: Hall E
Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) With Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) as Second-Line (2L) Treatment in Patients With Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study
Hanny Al-Samkari, MD
4:30 pm: 288-290
A Multicenter Study of Safety, Tolerability, and Effectiveness of Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia
Matthew J. Frigault, MD
6:00 pm: Hall D
Phase 1 Study of CART-Ddbcma for the Treatment of Subjects With Relapsed and /or Refractory Multiple Myeloma
Joan How, MD
6:00 pm: Hall D
Immunologic Responses to SARS-CoV-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations With Infections
David Kuter, MD, DPhil
6:00 pm: Hall D
Clinical Predictors of Response to Rilzabrutinib Therapy in Patients With Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study
David J. Lee, MD, MPH, MMSc
6:00 pm: Hall D
Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa
Orly Leiva, MD
6:00 pm: Hall D
Trends in All-cause and Cardiovascular Mortality Among Patients With Myeloproliferative Neoplasms: A Surveillance, Epidemiology, and End Results Database Analysis
Elizabeth O'Donnell, MD
6:00 pm: Hall D
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
Monday, December 12, 2022
Yi-Bin Chen, MD
10:30 am: 252-254
RGI-2001 Infusion for Prevention of Acute Gvhd After Allogeneic Hematopoietic Cell Transplantation
Michael Mazzola, BS
2:45 pm: 252-254
Cap-Independent Protein Translation in Hematopoiesis
Bimarzhan Assatova
4:30 pm: 391-392
KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients With Mature T and NK/T-Cell Lymphomas
Rebecca S. Karp Leaf, MD
4:30 pm: 388-390
Clinical Experience With Afamelanotide for the Protoporphyrias in the United States
David Kuter, MD, DPhil
4:30 pm: Great Hall AD
Moving Forward in Hemolytic Anemias: Acquired and Hereditary—Clinical Discussant for Cold Agglutinin Disease
Hanny Al-Samkari, MD
6:00 pm: Hall D
Mitapivat Improves Markers of Hemolysis and Erythropoiesis in Patients With Pyruvate Kinase Deficiency Irrespective of Hemoglobin Response
Leora S. Boussi, MD
6:00 pm: Hall D
Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients With Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era
Andrew Branagan, MD, PhD
6:00 pm: Hall D
Clinical Effectiveness and Long-term Serologic Responses of COVID-19 Vaccination in Patients With Multiple Myeloma and Waldenström Macroglobulinemia
Tejaswini Dhawale, MD
6:00 pm: Hall D
Perception of Prognosis, Quality of Life, and Distress in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy
Mihir Gupta, MD
6:00 pm: Hall D
A Rapid Genotyping Assay for CSF Accelerates Diagnosis and Treatment Initiation for CNS Malignancies
Orly Leiva, MD
6:00 pm: Hall D
Risk Factors for Major Adverse Cardiac Events and Bleeding in Patients With Myeloproliferative Neoplasms Admitted for Myocardial Infarction
Daniel Pearson, MD
6:00 pm: Hall D
Use of Clinical Decision Support to Improve the Laboratory Evaluation of Monoclonal Gammopathies
Jacob Soumerai, MD
6:00 pm: Hall D
A Phase 1 Study With the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination With Zanubrutinib (ZANU) in Patients (Pts) With Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data